Exclusive: Dialysis clinics provide new path for delivery of stockpiled COVID-19 antibody drugs in U.S.
FILE PHOTO: Healthcare workers treat patients infected with the coronavirus disease (COVID-19) at United Memorial Medical Center in Houston, Texas, U.S., December 28, 2020. REUTERS/Callaghan O Hare/File Photo reuters tickers
This content was published on December 30, 2020 - 15:38
December 30, 2020 - 15:38
By Deena Beasley
(Reuters) - Dialysis centers in the United States are rolling out COVID-19 antibody treatments this week, a new path for delivery of Eli Lilly and Regeneron drugs approved for emergency use but facing skepticism and logistical problems in some hospitals.
Supplies of the drugs are piling up as hospitals grapple with overflowing wards and mass vaccinations. Kidney dialysis patients are among those most at risk from COVID-19, which is especially deadly among people with chronic illnesses.
Article content
Dialysis centers in the United States are rolling out COVID-19 antibody treatments this week, a new path for delivery of Eli Lilly and Regeneron drugs approved for emergency use but facing skepticism and logistical problems in some hospitals.
Supplies of the drugs are piling up as hospitals grapple with overflowing wards and mass vaccinations. Kidney dialysis patients are among those most at risk from COVID-19, which is especially deadly among people with chronic illnesses.
We apologize, but this video has failed to load.
Try refreshing your browser, or Dialysis clinics provide new path for delivery of stockpiled COVID-19 antibody drugs in U.S. Back to video